Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics

An epidemic caused by COVID-19 in China turned into pandemic within a short duration affecting countries worldwide. Researchers and companies around the world are working on all the possible strategies to develop a curative or preventive strategy for the same, which includes vaccine development, drug repurposing, plasma therapy, and drug discovery based on Artificial intelligence. Therapeutic approaches based on Computational biology and Machine-learning algorithms are specially considered, with a view that these could provide a fast and accurate outcome in the present scenario. As an effort towards developing possible therapeutics for COVID-19, we have used machine-learning algorithms for the generation of alignment kernels from diverse viral sequences of Covid-19 reported from India, China, Italy and USA. Using these diverse sequences we have identified the conserved motifs and subsequently a peptide library was designed against them. Of these, 4 peptides have shown strong binding affinity against the main protease of SARS-CoV-2 (Mpro) and also maintained their stability and specificity under physiological conditions as observed through MD Simulations. Our data suggest that these evolutionary peptides against COVID-19 if found effective may provide cross-protection against diverse Covid-19 variants.

[1]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[2]  Longxiang Xie,et al.  Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV , 2020, Viruses.

[3]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[4]  Feng Zhao,et al.  Ensuring global access to COVID-19 vaccines , 2020, The Lancet.

[5]  L. Guddat,et al.  Structure of the RNA-dependent RNA polymerase from COVID-19 virus , 2020, Science.

[6]  Yanbing Ding,et al.  The epidemiology, diagnosis and treatment of COVID-19 , 2020, International Journal of Antimicrobial Agents.

[7]  R. Silverman,et al.  Antagonism of the Interferon-Induced OAS-RNase L Pathway by Murine Coronavirus ns2 Protein Is Required for Virus Replication and Liver Pathology , 2012, Cell Host & Microbe.

[8]  J. Lung,et al.  The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase , 2020, Journal of medical virology.

[9]  Johan Desmet,et al.  The dead-end elimination theorem and its use in protein side-chain positioning , 1992, Nature.

[10]  Armen Yuri Gasparyan,et al.  Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets , 2020, Clinical Rheumatology.

[11]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[12]  A. Kanhed,et al.  Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach , 2020, Molecular Diversity.

[13]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[14]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[15]  R. Awaluddin,et al.  Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study , 2020 .

[16]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[17]  P. Král,et al.  Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2 , 2020, ACS nano.

[18]  N. E. Mckinnon,et al.  Estimating the impact of the COVID-19 pandemic on rising trends in drug overdose mortality in the United States, 2018-2021 , 2022, Annals of Epidemiology.

[19]  Gajendra P.S. Raghava,et al.  PEPstr: a de novo method for tertiary structure prediction of small bioactive peptides. , 2007, Protein and peptide letters.

[20]  T. Palaga,et al.  Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.

[21]  G. Ippolito,et al.  SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection , 2020, Annals of Internal Medicine.

[22]  Maria Elena Bottazzi,et al.  The SARS-CoV-2 Vaccine Pipeline: an Overview , 2020, Current Tropical Medicine Reports.

[23]  W. Lim,et al.  Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome , 2004, The Lancet.

[24]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[25]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[26]  Philippe Brouqui,et al.  Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 , 2020, International Journal of Antimicrobial Agents.

[27]  Xuetao Cao.  COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[28]  Jianli Wu,et al.  Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study , 2020, The Lancet Infectious Diseases.

[29]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[30]  R. Schneider,et al.  Introduction to Molecular Dynamics , 2019, Molecular Dynamics Simulation of Nanocomposites Using BIOVIA Materials Studio, Lammps and Gromacs.

[31]  Stefan Elbe,et al.  Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.

[32]  J. Ziebuhr,et al.  Virus-encoded proteinases and proteolytic processing in the Nidovirales. , 2000, The Journal of general virology.

[33]  J. Huang,et al.  Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study , 2020, Clinical Microbiology and Infection.

[34]  S. Perlman,et al.  Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.

[35]  Zhangsuo Liu,et al.  Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients , 2020, The Journal of infectious diseases.

[36]  Asimul Islam,et al.  Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy , 2020, Bioscience reports.

[37]  Pavel V Baranov,et al.  Programmed ribosomal frameshifting in decoding the SARS-CoV genome , 2005, Virology.

[38]  J. Mixter.  Fast , 2012 .

[39]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[40]  Zhen Zhu,et al.  Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 , 2020, Journal of Infection.

[41]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[42]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[43]  Kwok-Hung Chan,et al.  Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Bin Zhang,et al.  Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, Chest.

[45]  Vijay Kumar,et al.  Amyotrophic Lateral Sclerosis: Current Therapeutic Perspectives , 2018, Pathology, Prevention and Therapeutics of Neurodegenerative Disease.

[46]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[47]  Kuo-Chen Chou,et al.  Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase , 2004, Analytical Biochemistry.

[48]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[49]  Wu Zhong,et al.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.

[50]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[51]  John R. Mascola,et al.  A strategic approach to COVID-19 vaccine R&D , 2020, Science.

[52]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[53]  J. Cramer,et al.  Evolution of the COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[54]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[55]  Yiu Chung Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[56]  Hydroxychloroquine , 2019, Reactions Weekly.

[57]  Kwok-Hung Chan,et al.  Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  M. Müller,et al.  Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience , 2018, Antiviral therapy.

[59]  G. Whittaker,et al.  Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites , 2009, Proceedings of the National Academy of Sciences.

[60]  J. Tanne.  Covid-19: FDA approves use of convalescent plasma to treat critically ill patients , 2020, BMJ.

[61]  Y. Guan,et al.  Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage , 2003, Journal of Molecular Biology.

[62]  S. Skariyachan,et al.  Recent Aspects on the Pathogenesis Mechanism, Animal Models and Novel Therapeutic Interventions for Middle East Respiratory Syndrome Coronavirus Infections , 2019, Front. Microbiol..

[63]  John L. Klepeis,et al.  Molecular dynamics - Scalable algorithms for molecular dynamics simulations on commodity clusters , 2006, SC.

[64]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[65]  D. Higgins,et al.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega , 2011, Molecular systems biology.

[66]  Y. Guan,et al.  Treatment with convalescent plasma for influenza A (H5N1) infection. , 2007, The New England journal of medicine.

[67]  Federico D. Sacerdoti,et al.  Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters , 2006, ACM/IEEE SC 2006 Conference (SC'06).

[68]  R. Tiwari,et al.  COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics , 2020, Human vaccines & immunotherapeutics.

[69]  Jonathan H. Epstein,et al.  Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.

[70]  N. Arinaminpathy,et al.  Prudent public health intervention strategies to control the coronavirus disease 2019 transmission in India: A mathematical model-based approach , 2020, The Indian journal of medical research.

[71]  Lynne Peeples.  News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine , 2020, Proceedings of the National Academy of Sciences.

[72]  Mikael Bodén,et al.  MEME Suite: tools for motif discovery and searching , 2009, Nucleic Acids Res..

[73]  Bing Han,et al.  COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission , 2020, Gastroenterology.

[74]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[75]  Yuan Shi,et al.  Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.

[76]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[77]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[78]  Zhìhóng Hú,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[79]  Md. Imtaiyaz Hassan,et al.  Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach , 2020, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.

[80]  A. Chughtai,et al.  Airborne or Droplet Precautions for Health Workers Treating Coronavirus Disease 2019? , 2020, The Journal of infectious diseases.